Samuel Peretsman, MD
Urology · Charlotte, NCNPI 1912946336
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,801 of the $9,601 with a category attached, or 81.3%. It is spread thinly across 42 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $2,818 and has fallen 91.5% since, to $241 in 2024.
Across 353 payments — averaging $27.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- Boston Scientific$1K
- Astellas Pharma US Inc$1K
- AbbVie$485
- Dendreon Pharmaceuticals LLC$414
- Johnson & Johnson$352
- plus $4K from 36 others
Across 48 payments — averaging $5665.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$201K
- Ferring International Pharmascience Center US$40K
- Ferring Pharmaceuticals AS$18K
- Astellas Pharma Global Development$13K
What the payments were for
- Consulting fees$1,78819%
- Food & beverage$7,80181%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JEVTANA$1,788
- AMS$335
- GENERAL - THERAPIES$164
- Sonablate$152
- Cryocare CS$152
- AquaBeam Robotic System$128
- Xofigo$125
- JELMYTO$124
- Lupron Depot$109
- MYRBETRIQ$109
How this compares
$9,601 in reported general payments places this provider in the 80th percentile of 434 urology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 13 | $165 |
Paid to pharmacies, not to this prescriber.
Other urology in Charlotte
- Michael KennellyCharlotte$1.3M
- Manish PatelCharlotte$84K
- Kris GastonCharlotte$32K
- Todd CohenCharlotte$18K
- Ornob RoyCharlotte$17K
- Maxim McKibbenCharlotte$15K
- Robert LippittSmithfield$11.4M
- John KasparRaleigh$1.1M
- Judd MoulDurham$1M
- Daniel GeorgeDurham$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.